Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

128.31 +1.43 (+1.13%)
Official Closing Price Updated: 4:10 PM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,605,366
Open 128.05
Bid (Size) 128.75 (1)
Ask (Size) 129.00 (1)
Prev. Close 126.88
Today's Range 127.49 - 130.46
52wk Range 75.56 - 138.28
Shares Outstanding N/A
Dividend Yield 1.38%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 of Europe’s ‘Magnificent 18’ Stocks That You Can Buy in the U.S.
The Magnificent Seven is so yesterday. The new trend is to invest in some of the top European stocks, dubbed the Magnificent 18. 
Via InvestorPlace
Eli Lilly Stock Jumps On Strong Earnings, Guidance As Zepbound Sales Easily Beat
Overall revenue fell short in Q1. Lilly stock is set to cross a key level. 
Via Investor's Business Daily

Performance

YTD
+25.66%
+25.66%
1 Month
+0.60%
+0.60%
3 Month
+17.69%
+17.69%
6 Month
+33.10%
+33.10%
1 Year
+53.28%
+53.28%

More News

Read More
Analyzing NYSE:NVO's Dividend Potential.
Via Chartmill
Decoding Novo Nordisk's Options Activity: What's the Big Picture?
Via Benzinga
Billionaire Investor Jim Simons Just Bought These 3 "Magnificent Seven" Stocks
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Is Viking Therapeutics Incredibly Undervalued?
Via The Motley Fool
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years
Via Benzinga
Is NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) a Strong Candidate for Quality Investing?
Via Chartmill
Why Novo Nordisk Topped the Market Today
Via The Motley Fool
Forget Nvidia, These Unstoppable Stocks Are Better Buys
Via The Motley Fool
1 Unstoppable Pharmaceutical Stock Investors Shouldn't Sleep On
Via The Motley Fool
MarketBeat Week in Review – 4/22 - 4/26
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
What Are Pricing Strategies for Ozempic And Wegovy With Potential Medicare Coverage Expansion? Senate Committee Questions Novo Nordisk
Via Benzinga
3 Biotech Stocks With Skyrocketing Potential: April 2024
Via InvestorPlace
Meet Eli Lilly's Secret Weapon in the Billion-Dollar Weight-Loss Drug Market
Via The Motley Fool
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
Via InvestorPlace
Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.
Via The Motley Fool
Better Buy: Pfizer vs. Viking Therapeutics
Via The Motley Fool
3 Stocks With the Potential to Surpass Analyst Expectations for 2024
Via InvestorPlace
Changing Frugal Eating Habits - How Novo Nordisk/Eli Lilly's Weight Loss Drugs Reshaping Food Spending
Via Benzinga
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Via MarketBeat
2 Everlasting Big Pharma Stocks to Buy Today and Hold Forever
Via The Motley Fool
MarketBeat Week in Review – 4/15 - 4/19
Via MarketBeat
Topics Economy
Exposures Interest Rates
3 Relatively Safe Growth Stocks You Can Buy and Hold
Via The Motley Fool
3 Biotech Stocks Set to Double by 2028
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.